The aim of our study was to evaluate the impact of additional gene mutations and cytogenetic abnormalities on the prognosis of AML patients with NPM1 and/or FLT3-ITD mutations, receiving intensive chemotherapy. Here, NPM1 is linked to acute myeloid leukemia.